A Phase 3, Randomized Trial Investigating the Safety, Tolerability, and Immunogenicity of V116, an Adult-Specific Pneumococcal Conjugate Vaccine, in Pneumococcal Vaccine-Naive Adults 18-64 Years of Age at Increased Risk of Pneumococcal Disease, STRIDE-8. (academic.oup.com)

Authors: Scott PT … Platt HL Journal: Clinical Infectious Diseases Published: 2026-02-25 DOI: https://doi.org/10.1093/cid/ciaf604